Furthermore, seralutinib, a highly potent (13- to 20-fold greater than imatinib) and specific inhaled tyrosine kinase inhibitor that targets PDGFR, CSF1R and c-KIT, has been specifically designed as a treatment for PAH (Figure 3C,D). Here, PDGFRB is linked to pulmonary arterial hypertension.